Prevalence of hepatitis C virus infection in porphyria cutanea tarda

Journal of Hepatology

Volumn 39, Issue 4, 2003, Pages 635-638

  Fargion, Silvia ^a   Fracanzani, Anna Ludovica ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; IRON; TUMOR NECROSIS FACTOR ALPHA; UROPORPHYRINOGEN DECARBOXYLASE;

ALCOHOL ABUSE; CLINICAL FEATURE; CONTRACEPTION; EDITORIAL; ENZYME ACTIVITY; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRON OVERLOAD; PHLEBOTOMY; PORPHYRIA CUTANEA TARDA; PREVALENCE; PRIORITY JOURNAL;

EID: 0141451824     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(03)00399-4     Document Type: Editorial

References (25)

1. Elder GH. Porphyria cutanea tarda. Semin Liver Dis 1998;18:67-75.
2. Bonkovsky HL, Barnard GF. The porphyrias. Curr Treat Options Gastroenterol 2000;3:487-500.
3. Bonkovsky L, Poh-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie A, Tattrie C, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998;27:1661-1669.
4. Mukerji SK, Pimstone NR, Burns M. Dual mechanism of inhibition of rat liver uroporphyrinogen decarboxylase activity for ferrous iron: its potential role in the genesis of porphyria cutanea tarda. Gastroenterology 1984;87:1248-1254.
5. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 1996;13:399-409.
6. Sampietro M, Piperno A, Lupica L, Arosio C, Vergani A, Corbetta N, et al. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology 1998;27:181-184.
7. Rocchi E, Gibertini P, Cassanelli M, Pietrangelo A, Jensen J, Ventura E. Hepatitis B virus infection in porphyria cutanea tarda. Liver 1986;6:153-157.
8. Hogan D, Card RT, Ghadially R, McSheffrey JB, Lane P. Human immunodeficiency virus infection and porphyria cutanea tarda. J Am Acad Dermatol 1989;20:17-20.
9. Fargion S, Piperno A, Cappellini MD, Sampietro M, Fracanzani AL, Romano R, et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992;16:1322-1326.
10. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002;36:1439-1445.
11. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC Groupe d'Etude et de Recherche en Medicine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000;79:47-56.
12. Gisbert JP, García-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 2003;39:620-627.
13. Wolff C, Armas R, Puig A, Krause P, Parraguez A. Hepatitis C virus infection in patients with porphyria. Rev Med Child 1994;122:294-298.
14. Malina L, Arenberger P, Kracikova J. The frequency of viral hepatitis C in patients with porphyria cutanea tarda. Cas Lek Cesk 1994;133:599-601.
15. Stolzel U, Kostler E, Koszka C, Stoffler-Meilicke M, Schuppan D, Somasundaram R, et al. Low prevalence of hepatitis virus infection in porphyria cutanea tarda in Germany. Hepatology 1995;21:1500-1503.
16. Murphy A, Dooley S, Hillary IB, Murphy GM. HCV infection in porphyria cutanea tarda. Lancet 1993;341:1534-1535.
17. Sampietro M, Fracanzani AL, Corbetta N, Amato M, Mattioli M, Molteni V, et al. High prevalence of hepatitis C virus type 1B in Italian patients with porphyria cutanea tarda. Ital J Gastroenterol Hepatol 1997;29:543-547.
18. Bulaj ZJ, Phillips JD, Ajioka RS, Franklin MR, Griffen LM, Guinee DJ, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 2000;95:155-171.
19. Hift RJ, Corrigall AV, Hancock V, Kannemeyer J, Kirsch RE, Meissner PN. Porphyria cutanea tarda: the etiological importance of mutations in the HFE gene and viral infection is population-dependent. Cell Mol Biol 2002;48:853-859.
20. Lamoril J, Andant C, Gouya L, Malonova E, Granchamp B, Martasel P, Deybac JC, Puy H. Hemochromatosis (HFE) and transferrin receptor-1 (TFRC1) genes in sporadic porphyria cutanea tarda (sPCT). Cell Mol Biol 2002;48:33-41.
21. Weiss G, Wachter H, Fuchs D. Linkage of cell-mediated immunity to iron metabolism. Immunol Today 1995;16:495-500.
22. Dongiovanni P, Valenti L, Fracanzani AL, Taioli E, Cappellini MD, Fargion S. QTNF-alpha promoter polymorphisms in Italian patients with porphyria cutanea tarda. Dig Liver Dis 2003; in press.
23. Fargion S, Fracanzani AL, Rossini A, Borzio M, Riggio O, Belloni G, et al. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol. 2002;97:1204-1210.
24. Tung BY, Emond MJ, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C, iron status and disease severity relationship with HFE mutations. Gastroenterology 2003;124:318-326.
25. Pietrangelo A. Hemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology 2003;124:1509-1523.